Hovione Receives Patent Approval for XCaps DPI

Article

The device is an inexpensive, easy-to-use capsule-based DPI with high efficiency powder dispersion and has the versatility to treat a range of pulmonary diseases.

The European Patent Office has granted a patent for Hovione's dry powder inhaler (DPI). The device is an inexpensive, easy-to-use capsule-based DPI with high efficiency powder dispersion and has the versatility to treat a range of pulmonary diseases including asthma, COPD as well as infection, which usually requires large-dose delivery.

Lung fractions in excess of 70% have been achieved from a device that only requires two steps to inhalation and only has two components plus a dust cover. XCaps is suitable for inhalation applications where minimal training of patients is desirable.

Source: Hovione

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content